Roger Henriksson

Research interests

Publications

• European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

  Neuro-Oncology · 2022 · 10.1093/neuonc/noac196

• Cancer patients’ use of complementary and alternative medicine in Sweden: a cross-sectional study

  BMC Complementary and Alternative Medicine · 2019 · 10.1186/s12906-019-2452-5

• European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30345-5

• European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30194-8

• EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

  Annals of Oncology · 2017 · 10.1093/annonc/mdx221

• Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome

  Nature Communications · 2016 · 10.1038/ncomms11843

• EANO guidelines for the diagnosis and treatment of meningiomas

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30321-7

• Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.61.5005

• Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00076-5

• EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70011-7

• Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1308345

• Genome-wide association study of glioma and meta-analysis

  Human Genetics · 2012 · 10.1007/s00439-012-1212-0

• Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70265-6

• Detectable clonal mosaicism and its relationship to aging and cancer

  Nature Genetics · 2012 · https://doi.org/10.1038/ng.2270

• FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.38.1095

• Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review

  Journal of Neuro-Oncology · 2011 · 10.1007/s11060-011-0565-x

• Genome-wide association study identifies five susceptibility loci for glioma

  Nature Genetics · 2009 · https://doi.org/10.1038/ng.407

• Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA)

  Radiotherapy and Oncology · 2008 · 10.1016/j.radonc.2006.04.015

• Breast Cancer Survival Is Associated with Telomere Length in Peripheral Blood Cells

  Cancer Research · 2008 · 10.1158/0008-5472.can-07-6497

• Vascular Endothelial Growth Factor Polymorphisms in Relation to Breast Cancer Development and Prognosis

  Clinical Cancer Research · 2005 · 10.1158/1078-0432.ccr-04-1803

• LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation

  The EMBO Journal · 2004 · 10.1038/sj.emboj.7600342

• Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

  Annals of Oncology · 2001 · 10.1023/a:1008382516636

• Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment

  Journal of Clinical Oncology · 2000 · 10.1200/jco.2000.18.7.1423

• Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.

  Journal of Clinical Oncology · 1998 · 10.1200/jco.1998.16.9.3121

• Parotid gland function during and following radiotherapy of malignancies in the head and neck

  European Journal of Cancer · 1992 · 10.1016/s0959-8049(05)80076-0

Current projects

No projects listed.